Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Examination of the MAPK pathway gene expression in patient samples

ABSTRACT: Microarray analysis of total RNA isolated from samples of circulating tumor cells from 7 patients before romidepsin infusion (0 hours), at 4 h after initiation of the infusion (4 hours) and 24 h after initiation of the infusion (24 hours). MAPK pathway related genes were selected to see differences between patient blood samples after roomidepsin treatment at 0 hour, 4 hour and 24 hour.

ORGANISM(S): Homo sapiens

SUBMITTER: Louise Showe

PROVIDER: E-GEOD-45405 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

Chakraborty Arup R AR Robey Robert W RW Luchenko Victoria L VL Zhan Zhirong Z Piekarz Richard L RL Gillet Jean-Pierre JP Kossenkov Andrew V AV Wilkerson Julia J Showe Louise C LC Gottesman Michael M MM Collie Nathan L NL Bates Susan E SE

Blood 20130326 20

To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romidepsin and were resistant to apoptosis induced by apicidin, entinostat, panobinostat, belinostat, and vorinostat. A custom TaqMan array identified increased insulin receptor (INSR) gene expression; imm ...[more]

PMID: 23532732

Similar Datasets

Examination of the MAPK pathway gene expression in patient samples

Project description:Microarray analysis of total RNA isolated from samples of circulating tumor cells from 7 patients before romidepsin infusion (0 hours), at 4 h after initiation of the infusion (4 hours) and 24 h after initiation of the infusion (24 hours).

2013-06-03 | GSE45405 | GEO

Brief Hydrocortisone Infusion Differentially Influences Blood Leukocyte and Monocyte Gene Expression Before and After Endotoxin Administration in Humans (supported by NIH grant GM34695)

Project description:Fourteen human subjects (18-40 years of age) were studied. The control group (saline + LPS [n = 7]) received a 12 hour infusion of saline and the experimental group (cortisol + LPS [n = 7]) received a 12 hour infusion of cortisol (3 µg/kg/min). After 6 hours of saline or cortisol infusion, intravenous lipopolysaccharide (2 ng/kg) was administered to all subjects. Blood samples were collected at -24 hours, 0 hours, 6 hours and 24 hours relative to LPS administration at 0 hours. Leukocytes and monocytes were isolated from these blood samples, total RNA extracted, and microarray analyses performed using Affymetrix Focus GeneChips®.

2010-05-21 | GSE21909 | GEO

A Novel Model of Common TLR4- and Injury induced transcriptional themes in Human Leukocytes (supported by NIH grant GM34695)

Project description:Fifteen human volunteer subjects (18-40 years of age) and 5 Trauma patients were studied. One volunteer group (saline + LPS [n = 8]) received a 12 hour infusion a second volunteer group (cortisol + LPS [n = 7]) received a 12 hour infusion of cortisol (3 µg/kg/min). After 6 hours of saline or cortisol infusion, intravenous lipopolysaccharide (2 ng/kg) was administered to all subjects. Blood samples were collected at 0 hours, 6 hours and 24 hours relative to LPS administration at 0 hours. Blood samples were drawn from a grounp of Trauma patients shortly (day1-5) after admission and later in their ICU stay (day 5-7). Leukocytes were isolated from these blood samples, total RNA extracted, and microarray analyses performed using Affymetrix Focus GeneChips® on samples yeilding sufficent quantity and quality RNA for analysis.

2010-06-11 | GSE22278 | GEO

Brief Hydrocortisone Infusion Differentially Influences Blood Leukocyte and Monocyte Gene Expression Before and After Endotoxin Administration in Humans (supported by NIH grant GM34695)

Project description:Fourteen human subjects (18-40 years of age) were studied. The control group (saline + LPS [n = 7]) received a 12 hour infusion of saline and the experimental group (cortisol + LPS [n = 7]) received a 12 hour infusion of cortisol (3 ug/kg/min). After 6 hours of saline or cortisol infusion, intravenous lipopolysaccharide (2 ng/kg) was administered to all subjects. Blood samples were collected at -24 hours, 0 hours, 6 hours and 24 hours relative to LPS administration at 0 hours. Leukocytes and monocytes were isolated from these blood samples, total RNA extracted, and microarray analyses performed using Affymetrix Focus GeneChips. Blood samples were collected at (-24)hr, 0hr, 6hr, and 24hr in relation to the LPS infusion. For both saline and cortisol treated subjects, infusion was started at (-6) hr and continued to (+6) hr.

2010-06-08 | E-GEOD-21909 | biostudies-arrayexpress

A Novel Model of Common TLR4- and Injury induced transcriptional themes in Human Leukocytes (supported by NIH grant GM34695)

Project description:Fifteen human volunteer subjects (18-40 years of age) and 5 Trauma patients were studied. One volunteer group (saline + LPS [n = 8]) received a 12 hour infusion a second volunteer group (cortisol + LPS [n = 7]) received a 12 hour infusion of cortisol (3 Âµg/kg/min). After 6 hours of saline or cortisol infusion, intravenous lipopolysaccharide (2 ng/kg) was administered to all subjects. Blood samples were collected at 0 hours, 6 hours and 24 hours relative to LPS administration at 0 hours. Blood samples were drawn from a grounp of Trauma patients shortly (day1-5) after admission and later in their ICU stay (day 5-7). Leukocytes were isolated from these blood samples, total RNA extracted, and microarray analyses performed using Affymetrix Focus GeneChipsÂ® on samples yeilding sufficent quantity and quality RNA for analysis. Blood samples were collected at 0hr, 6hr, and 24hr in relation to the LPS infusion. For both saline and cortisol treated subjects, infusion was started at (-6) hr and continued to (+6) hr.

2010-06-23 | E-GEOD-22278 | biostudies-arrayexpress

Multi-omic map revealed PPARα activation protecting against myocardial ischemia/reperfusion injury by maintaining cardiac metabolic homeostasis [bulk RNA-seq]

Project description:The rats were subjected to left anterior descending (LAD) coronary artery ligation for 1 hour, 6 hours (MI1h and MI6h) and 24 hours (MI24h) along with Sham controls (Sham), and 1-hour, 6-hour ischemia followed by reperfusion (MI1h/R and MI6h/R, mimicking early time reperfusion (ETR) and late time reperfusion (LTR), respectively) followed by heart tissue collection 24 hours post MI to mimic the MI/R injury in AMI patients and pretreatment with FDA-approved PPARα agonist fenofibrate for each group.

2024-08-01 | GSE240847 | GEO

RNA-seq reveals changes in the astrocyte transcriptome following Borrelia burgdorferi infection

Project description:mRNA profiles of astrocytes infected with Borrelia burdorferi for 24 hours, 48 hours, and 24 hour uninfected controls were generated by deep sequencing, in triplicate, using Illumina HiSeq.

2017-02-01 | GSE85143 | GEO

microRNA changes in astrocytes following Borrelia burgdorferi infection

Project description:miRNA profiles of astrocytes infected with Borrelia burgdorferi for 24 hours, 48 hours, and 24 hour uninfected controls were generated by deep sequencing, in duplicate, using Illumina MiSeq.

2017-02-01 | GSE85142 | GEO

A study assessing the similarity of Avastin (Registered Trademark) and the trial drug BAT1706.

Project description:Interventions: Three Bevacizumab Preperations Arm 1:BAT1706 100 mg in 4 mL - 1mg/kg Recombinant humanised monoclonal antibody - bevacizumab 1 time only Intravenous infusion. Arm 2: Avastin (Registered Trademark) United States-licenced (bevacizumab) 100 mg in 4 mL- 1mg/kg Recombinant humanised monoclonal antibody - bevacizumab 1 time only Intravenous infusion. Arm 3: Avastin (Registered Trademark) European Approved (bevacizumab) 100 mg in 4 mL- 1mg/kg Recombinant humanised monoclonal antibody - bevacizumab 1 time only Intravenous infusion. As the Infusion will be administered while the participants are inpatients of the facility, no strategy for adherence is required. Primary outcome(s): To establish pairwise pharmacokinetic (PK) similarity between BAT1706, EU Avastin and US-Avastin after a single intravenous (IV) infusion in healthy male subjects. The primary PK parameters will consist of: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf).[Blood samples for analysis of serum concentrations of the study drugs will be collected at the following specified times to perform a comparison of PK similarity. Pre infusion - 0 hour or within 1 hour prior to the start of the infusion. Mid infusion - at 45 minutes - relative to the start of infusion. End of infusion - 1 hour, 2 hours, 5 hours, 8 hours, 12 hours from the end of infusion, and 24 hours (Day 2), 48 hours (Day 3), 96 hours (day 5), 168 hours (day 8), 240 hours (Day 11), 336 hours (Day 15), 504 hours (day 22), 672 hours (Day 29), 840 hours (Day 36), 1008 hours (Day 43), 1344 hours (Day 57), 1680 hours (Day 71), 2016 hours (Day85) and 2352 hours (Day 99) post start of infusion. ] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Pharmacokinetics

| 2463333 | ecrin-mdr-crc

Transcription profiling of rat animal model of extremity melanoma after treatment with ADH-1 in combination with melphalan

Project description:To identify patterns of change in gene expression that correlated with drug treatment (saline control, ADH-1 alone, melphalan alone and ADH-1 plus melphalan) in our animal model of regional therapy for extremity melanoma we evaluated gene expression using microarray genechips and a Pearson correlation analysis. Genes were ranked according to the degree to which expression correlated with systemic ADH-1 treatment alone or in combination with regional melphalan. Tissue samples were harvested at 4, 24 and 48 hours after treatment with melphalan. Specific cellular pathways associated with drug treatment were identified using gene set enrichment analysis (GSEA). Experiment Overall Design: Sample size was 2 rats for each drug treatment group at both the 4 and 24 hour time points. At the 48 hour time point sample size was 1 rat for each drug treatment group. ADH-1 treatment preceded melphalan by 1 hour. ADH-1 treatment was repeated at 24 and 48 hrs. Tissue was harvested for RNA analysis at 4, 24 and 48 hours after completion of isolated limb infusion with melphalan (and 1 hour after an ADH-1 dose).

2008-11-07 | E-GEOD-8615 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data